Rare Disease Day 2022: Supporting patients, celebrating advancements

February 28 is Rare Disease Day, a day dear to the hearts of many at Labcorp. The day is observed to raise awareness and give support to the more than 300 million people worldwide living with rare diseases, as well as their family members and caretakers.

TSCA and US state legislation: Navigating your chemical or agrochemical through the federal and state regulatory landscape in the USA

Registering your chemical or crop protection product with the US EPA under TSCA or FIFRA is the first and biggest step in its regulatory journey in the USA. But you will also need to navigate state-specific legislation and regulations, and for crop chemicals this includes registering in every state where they will be used.

Advancing inhalation toxicology capabilities to support chemical testing

Respiratory exposure to chemicals or agrochemicals poses potential risk to human health, especially to workers handling these products. Whether preparing a solution, dusting or spraying crops, or cleaning equipment, opportunities for inadvertent inhalation is a risk that can potentially lead to toxic effects, both acute and chronic. That’s why identifying potential risk posed by respiratory exposure to a chemical or agrochemical is a mandatory component of toxicology studies in regulatory submissions for new registrations and, often, for re-registrations. In addition to the requirement, inhalation studies themselves are complex and challenging, as delivery of test articles via the inhalation route requires careful attention to substance aerosolization and particle size as well as constant control and monitoring over a prolonged time.

Labcorp Patient Access Solutions Asembia discussions for 2022

At industry events, there are the discussions you hear inside of sessions, and there are also the discussions that take place outside of sessions. During the October 2021 Asembia event, we heard several common themes among attendees, clients, prospects and vendors

Cell & Gene Therapy Answers: Preclinical Oncology

As the landscape of cell therapy continues to evolve, so are the tools to assess the efficacy of cell therapy in the preclinical space. To better understand Labcorp’s preclinical oncology role in cell therapy development, we spoke with Sheri Barnes, associate director of scientific development for Labcorp preclinical oncology, who assists drug development sponsors in study design and model selection for preclinical oncology studies, along with David Draper, associate director of scientific development for Labcorp preclinical oncology who helps sponsors understand how in vitro services can be used effectively to address their preclinical investigational needs.

Detecting measurable residual disease (MRD) in hematological malignancies using flow cytometry

A patient may be in complete remission during or after a cancer treatment, but a few cancer cells may persist in what is known as residual disease. To better inform prognoses, understand treatment decisions, predict a patient’s overall survival or understand the potential for disease relapse, it is important to have the ability to detect and quantify these malignant cells.

Eight instrument considerations in flow cytometry

Whether it’s developing fit-for-purpose, customized flow assays, or optimizing the most appropriate off-the-shelf assay, the Labcorp Central Laboratory Services flow cytometry specialty testing team generates high-quality, clinically relevant and actionable data for your drug development programs. Here, we discuss how we choose our flow cytometry instruments to execute multi-site operations and extract the most data possible from limited clinical samples.

Identifying alternative supplies to address global supply chain issues and deliver custom clinical trial kits

Disruption across the global supply continues to challenge clinical trial operations, so the Labcorp Global Supply Chain Sourcing and Procurement team has leveraged Labcorp’s scale and expertise to reconfigure relationships with manufacturers and develop new processes for identifying and qualifying alternative supplies for customized clinical trial kits.

The evolution of Central Laboratory planning and forecasting to enable more efficient study delivery

Fostering trust with customers starts with delivering study materials on time, underscoring the importance of planning and forecasting processes to meet current demands. While the pandemic highlighted the need to adjust approaches and address the industry’s supply chain disruptions, it also brought forth enhanced planning and forecasting methods at Labcorp.

Application of decentralized clinical trials on AI-focused dermatology

The use of virtual tools and telecommunications skyrocketed during the COVID-19 pandemic as the world adjusted to new ways of working. In the clinical trials sector, this propelled an increasing adaptation to the decentralized clinical trial (DCT) approach to support research and minimize on-site burden on investigators and patients. With remote mobile device applications and smartphone photography widely accessible, new opportunities to streamline efficiencies and create an enhanced overall experience in dermatology clinical studies abound.